On The Radar – 15th Edition
By
A sharp opinion piece argues that pharmaceutical manufacturers are prioritizing shareholder returns over genuine innovation. Through tactics like “evergreening,” companies make minor tweaks to existing drugs to secure new patents and delay generics, extending high prices for years. Meanwhile, spending on marketing and stock buybacks often outpaces true R&D investment.
➡ Why it matters: Patent strategy remains one of the most powerful cost drivers in pharmacy. Until competition is structurally restored, pricing pressure will persist.
Despite decades of reform, the U.S. remains the world’s most expensive healthcare system. Drug pricing, patent extensions, PBM incentives, and expiring ACA subsidies continue to drive premiums higher while shrinking the insured risk pool.
➡ Why it matters: Affordability challenges are systemic, not temporary. Employers must design benefits with long-term volatility in mind.
All 50 states now regulate PBMs, and new federal laws are accelerating oversight. Compensation tied to list prices is being dismantled, fiduciary expectations are rising, and reporting requirements are expanding at both state and federal levels.
➡ Why it matters: The era of opaque rebate models is ending. PBM contracts must evolve to meet a far more demanding compliance environment.
A proposed Department of Labor rule would require PBMs and affiliated consultants to disclose rebates, spread pricing, and indirect compensation before contracts are signed. Employers would also gain formal audit rights.
➡ Why it matters: Fiduciary oversight is shifting from passive review to active verification. Employers will soon have both the authority and the obligation to scrutinize PBM economics.
As GLP-1s and gene therapies reshape pharmacy spend, experts argue that employers must move beyond simple exclusions or blanket coverage. Precision coverage, carve-outs, and specialty stop-loss models are emerging as financial safeguards.
➡ Why it matters: High-cost medications require strategic design, not reactive plan edits.
Transparency remains murky across healthcare markets, but employers still control vendor selection and oversight. The most effective lever is demanding granular reporting and holding partners to measurable standards.
➡Why it matters: True transparency is not about regulation alone. It is about governance discipline.
The Consolidated Appropriations Act, 2026 requires PBMs to pass through 100% of manufacturer rebates and provide drug-level reporting to plans. Spread pricing faces federal restrictions, and audit rights expand significantly.
➡Why it matters: Federal reform is moving from discussion to enforcement. Employers now have stronger legal footing to demand alignment.
The sweeping PBM Reform Act introduces granular reporting, spread pricing bans, and expanded fiduciary accountability. Pharmacies gain protections, while employers gain unprecedented visibility into cost flows.
➡Why it matters: The “black box” model is under structural dismantling.
New bipartisan legislation would force separation between insurers, PBMs, and provider networks to reduce conflicts of interest. Vertical integration is being framed as a root cause of inflated costs.
➡ Why it matters: Structural healthcare reform is no longer fringe rhetoric. Consolidation itself is under attack.
New rebate pass-through mandates and reporting rules could spark ERISA class-action lawsuits similar to those seen in retirement plans. Employers are being warned to document oversight carefully.
➡ Why it matters: Transparency increases visibility, and visibility increases legal exposure.
GLP-1 leaders continue posting record earnings while legacy manufacturers brace for patent cliffs and Medicare price negotiations. M&A activity is surging as companies buy pipeline replacements.
➡ Why it matters: Revenue pressure drives pricing strategy. Market shifts upstream will ripple downstream to employer plans.
Pharma brands dominated Super Bowl advertising with high-profile GLP-1 campaigns, even as regulators hint at tightening advertising scrutiny. Direct-to-consumer messaging is scaling rapidly.
➡ Why it matters: Demand is being fueled at record levels just as payers and regulators attempt to contain costs.
Final Thoughts
Pharmacy economics are undergoing structural change at every level: legislative, legal, regulatory, and market-driven. Transparency mandates are rising while pricing pressure intensifies. Employers who treat pharmacy as a governed financial asset, not a passive benefit, will be better positioned for what comes next.
We’ll be back in two weeks with more news you need to know. If you’d like a custom analysis or want to explore SHARx program options for your clients, contact us!
Stay Connected with SHARx
Subscribe to our newsletter for monthly updates from our CEO, curated industry news, insights from our in-house pharmacist, the latest blog posts, and more. Just fill out the form to stay informed.
Newsletter Sign-up
Be the first to learn what’s new with SHARx.